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Diagnostic Yield of Percutaneous Image-
Guided Tissue Biopsy of Focal Hepatic
Lesions in Cancer Patients
Ten Percent Are Not Metastases From the Primary Malignancy
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BACKGROUND: The diagnostic yield was evaluated of percutaneous image-guided tissue biopsy of hepatic lesions
identified on computed tomography performed for staging of a primary malignancy, and it was determined how of-
ten the biopsy result was unexpectedly negative, benign, or secondary to a second unknown malignancy. METHODS:
In a retrospective investigation from 1998 through 2008, 580 patients with primary malignancies had indeterminate
focal hepatic lesions and underwent percutaneous image-guided biopsy; 369 patients had lesions in their liver at first
cross-sectional imaging, performed for staging; 211 patients had a negative liver imaging study, followed by the sub-
sequent appearance of at least 1 indeterminate suspicious lesion. The results of percutaneous image-guided tissue
biopsies were compared with the histology of the primary malignancy. RESULTS: Liver biopsies were performed in
580 patients (288 men and 292 women; age, 25-92 years; mean age, 61 years). The most common primary malignan-
cies were pancreatic (n ¼ 96), breast (n ¼ 85), melanoma (n ¼ 57), esophageal (n ¼ 51), lung (n ¼ 47), colorectal (n
¼ 37), and urothelial tumors (n ¼ 26). Biopsy results were positive for malignancy in 528 (91%) cases. Among the
positive biopsies, 29 (5%) cases had pathology results different from the primary tumor. Of the 52 biopsies negative
for malignancy, 20 yielded a specific benign diagnosis, and 32 were nondiagnostic. CONCLUSIONS: If all liver lesions
had been assumed to be metastases, as expected secondary to the known primary tumor, then the true or presumed
alternate diagnosis would have been missed in 60 (10.3%) of the 580 cases. The authors did not attempt to deter-
mine whether actual clinical management changed based on these 60 liver biopsy results, so this number is an upper
bound on management change. On the basis of these results, and given the minimal complication rate of liver biopsy,
the authors suggest that liver biopsy should still be performed in the types of cases studied here, despite the finding
that the vast majority of biopsies produced the expected result and presumably did not change patient management.
Cancer 2011;117:4041–8. VC 2011 American Cancer Society.
KEYWORDS: biopsy, diagnostic yield, hepatic lesions, liver.
In patients with cancer, tissue diagnosis, often by percutaneous image-guided needle biopsy, is typically required to estab-
lish a definitive diagnosis and to guide management. In some cases, at the time of initial presentation with suspected meta-
static cancer, the primary lesion and its tissue type may be known and even have been treated; the suspected metastases
may have been known at the time of initial primary neoplasm diagnosis or may present at a later time, indicating the devel-
opment of new metastatic disease. In other cases of suspected metastasis, imaging may have identified a suspected primary
lesion, although a biopsy may not yet have been performed, and the specific tissue type may be unknown. In yet another
set of cases, the primary lesion is a mystery and not only may a biopsy of suspected metastases prove metastatic disease, but
the tissue type discovered may be sufficient for therapy, or indicate the likely primary tumor and assist in planning diag-
nostic tests to uncover it.
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Percutaneous image-guided liver biopsy for sus-
pected metastasis is a common procedure in our institu-
tion. We wondered howmuch information is provided by
such biopsies in the various situations described above;
how often do they simply confirm what is already known?
Specifically, we wondered how often new hepatic lesions
(or suspicious lesions seen on first imaging) are negative,
benign, or arise from a malignancy not suspected from ei-
ther imaging detection of a suspected primary malignancy
or from a known primary lesion. Perhaps in some clinical
situations, it might be possible to accept imaging findings
as proof of metastasis and avoid the biopsy procedure. We
retrospectively reviewed 11 years of percutaneous image-
guided liver biopsies to evaluate the diagnostic yield of
percutaneous image-guided tissue biopsy of hepatic
lesions identified on computed tomography (CT) per-
formed for staging of a primary malignancy and to deter-
mine how often the biopsy result was unexpectedly
negative, benign, or secondary to a second unknown
malignancy.
MATERIALS AND METHODS
This study was performed in compliance with the US
Health Insurance Portability and Accountability Act.
Institutional review board approval was obtained for the
review of subjects’ medical records. Because of the retro-
spective nature of the investigation, patient informed con-
sent was not required.
By using our departmental biopsy database, all per-
cutaneous image-guided liver biopsies performed in
adults from January 1998 through December 2008 were
identified. By using our institution’s electronic data repos-
itory, the medical records of the patients undergoing these
biopsies were reviewed to assess inclusion and exclusion
criteria. Patients underwent liver biopsy as a part of their
clinical care, and these lesions were sufficiently suspicious
by clinical and imaging characteristics to warrant biopsy.
All of these biopsies were performed to answer clinical
questions. None of these biopsies was required as part of a
research protocol or treatment study. No attempt was
made to retrospectively re-evaluate the appropriateness of
the clinical decision making, because the goal of the study
was to evaluate liver biopsy as used in clinical practice.
Cases were excluded if the biopsy was performed for
reasons other than the determination of malignancy (eg,
to confirm microabscesses in the liver). Cases were also
excluded if the goal of the biopsy was the first determina-
tion of malignancy, including cases where the lesion was a
presumed primary neoplasm of the liver or cases where
the primary tumor was completely unknown (both loca-
tion and tissue type) at the time of the biopsy. These latter
exclusions were made because in these situations, imaging
findings of hepatic lesions could not be a potential substi-
tute for hepatic biopsy. Cirrhosis of the liver was not a spe-
cific exclusion criterion, but these patients were excluded
when the biopsy was performed to diagnose primary he-
patic malignancy.
Cases were included if the primary tumor was
known from biopsy or surgical resection of a primary
lesion and/or other metastases in organs other than the
liver. Cases were also included if a specific primary tumor
was suspected from imaging tests (such as an adenocarci-
noma of the pancreas). Cases were subdivided based on
whether the patient had previously undergone imaging
that showed a metastasis-free liver before an imaging
study that was suggestive of newly discovered metastases
(Group 1), or whether the first available imaging showed
lesions suspicious for metastases (Group 2).
For the study population, patient medical records
were reviewed for demographic information, complica-
tions from the liver biopsy, histology of the primary tu-
mor (if determined), and the results of any biopsies
performed. In cases where the index biopsy did not con-
firm the suspected metastatic disease, the medical record
was reviewed to identify the next steps taken clinically,
such as a second biopsy, but specifically to determine
whether negative biopsies were treated clinically as posi-
tive results although the histology did not confirm the
presence of metastases. The data were analyzed with de-
scriptive statistics.
RESULTS
From January 1998 through December 2008, 1958 per-
cutaneous image-guided hepatic biopsies were performed.
Of these, 956 liver biopsies were of suspected metastases,
and 580 met the inclusion criteria. Of these 580 biopsies,
499 (86.0%) matched the pathology of the primary
malignancy (Fig. 1), whereas 81 (14.0%) did not.
The 580 patients were composed of 288 men and
292 women, with a mean age of 61 years (range, 25-92
years). Biopsies were performed under ultrasound guid-
ance in most cases (n¼ 571); CT was used for guiding bi-
opsy in only 9 cases. The most common primary
malignancies were pancreatic, breast, melanoma, esopha-
geal, lung, colorectal, and urothelial tumors. A complete
list of primary tumors and biopsy results are provided in
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Tables 1 and 2. The distribution of primary tumors
reflects our referral pattern as a quaternary academic med-
ical center.
The primary neoplasm was proven by pathology in
468 (80.7%) of 580 cases and determined by imaging in
112 (19.3%) of 580 cases. In the latter category, imaging
in addition to multidisciplinary tumor board decisions—
which deemed the diagnosis to be primary malignancy—
were considered sufficient.
Prior CT scans that showed a liver free of lesions sus-
picious for metastases (Group 1 patients) were available in
211 patients. The remaining 369 patients (Group 2) pre-
sented for biopsy with an initial study showing suspicious
liver lesions, and no prior negative CT, magnetic reso-
nance imaging (MRI), or positron emission tomography
scan.
Of the 499 biopsies in which the biopsy matched
the pathology of the primary malignancy, 392 (78.6%)
had histologic proof of the primary malignancy, whereas
107 (21.4%) had imaging diagnosis of the primary tumor,
and 188 (37.7%) were in Group 1 patients, whereas 311
(62.3%) were in Group 2 patients.
In 29 (5.0%) of 580 cases, liver biopsy returned a
malignant result that was different from the presumed pri-
mary malignancy (Fig. 2). All but 1 of these cases occurred
in patients for whom histologic proof of the primary
malignancy was known. Ten (34%) of 29 occurred in
Group 1 patients, and 19 (66%) of 29 occurred in Group
2 patients.
A total of 52 liver biopsies yielded results that were
negative for malignancy. Of these negative results, 20
(38%) of 52 yielded a histologic diagnosis of a benign
Figure 1. (Top) Axial computed tomography section from a
60-year-old patient with biopsy-proven pancreatic adenocar-
cinoma shows pneumobilia related to a biliary stent, but no
lesions within the liver. (Bottom) A follow-up study 20
months later shows a new low-attenuation lesion (arrow)
within the left lobe of the liver. Biopsy of this lesion was posi-
tive for metastatic adenocarcinoma.
Table 1. Primary Tumors (Known or Clinically Suspected by
Imaging) in 580 Liver Biopsies








Multiple primaries 25 4.3
Leukemia/lymphoma 23 4.0
Cholangiocarcinoma 21 3.6
Renal cell 20 3.4












Merkel cell 2 0.3
Thymic 2 0.3
Thyroid 2 0.3









Parotid adenoid cystic 1 0.2
Peripheral nerve sheath tumor 1 0.2
GIST indicates gastrointestinal stromal tumor.
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abnormality that could explain the imaging anomaly (Fig.
3), such as focal nodular hyperplasia or hemangioma. The
remaining 32 (62%) of 52 biopsies were nondiagnostic:
either a histologic diagnosis of normal liver tissue or a tis-
sue sample that was deemed inadequate for diagnosis of
malignancy. The subsequent clinical course of these
patients was reviewed. Five (16%) of 32 patients with
nondiagnostic biopsies were lost to follow-up after their
biopsy. Of the remaining 27 patients, 15 (56%) of 27
were treated by the clinical service for presumed meta-
static disease, 4 (15%) of 27 underwent 1 or more addi-
tional liver biopsies, and 8 (30%) of 27 were not treated as
metastatic disease and did not undergo subsequent biop-
sies (Table 3). Of the 4 patients who underwent a second
liver biopsy, none returned a histologic diagnosis of
malignancy. One patient was subsequently treated as
being free of metastases. A second patient underwent a
third liver biopsy, which was also negative for malignancy,
and then had the liver mass resected with a final diagnosis
of benign focal nodular hyperplasia. A third patient
underwent endoscopic ultrasound, with a biopsy positive
for malignancy consistent with the known primary neo-
plasm (Fig. 4). The fourth patient underwent endoscopic
retrograde cholangiopancreatography with histologic di-
agnosis of a second malignancy (cholangiocarcinoma;
original primary colorectal cancer).
Excluding 5 patients lost to follow-up after a single
nondiagnostic liver biopsy, patient management was
known or presumed in 575 patients (Table 4). We













1 176 (30.3) 216 (37.2) 392 (67.5)
5 12 (2.1) 95 (16.4) 107 (18.5)
Subtotal 188 (32.4) 311 (53.6) 499 (86.0)
Biopsy malignant but different from expected primary
2 10 (1.7) 18 (3.1) 28 (4.8)
6 0 (0) 1 (0.2) 1 (0.2)
Subtotal 10 (1.7) 19 (3.3) 29 (5.0)
Nondiagnostic
3 10 (1.7) 20 (3.4) 30 (5.2)
7 0 (0) 2 (0.3) 2 (0.3)
Subtotal 10 (1.7) 22 (3.8) 32 (5.5)
Benign
4 3 (0.5) 15 (2.6) 18 (3.1)
8 0 (0) 2 (0.3) 2 (0.3)
Subtotal 3 (0.5) 17 (2.9) 20 (3.4)
Total 211 (36.4) 369 (63.6) 580 (100)
The following code was used. Primary malignancy known from histologic
diagnosis: 1 ¼ liver biopsy matches pathology primary; 2 ¼ liver biopsy
malignant but different from pathology primary; 3 ¼ negative (nondiagnos-
tic); 4 ¼ benign. Primary malignancy known from clinical diagnosis (no tis-
sue diagnosis): 5 ¼ liver biopsy matches clinical diagnosis; 6 ¼ liver biopsy
malignant but different from clinical diagnosis; 7 ¼ negative (nondiagnostic);
8 ¼ benign.
Numbers in parentheses represent percentages of the total 580 cases. Line
and column totals vary due to rounding.
Group 1 consists of patients who had previously undergone imaging that
showed a metastasis-free liver before an imaging study that was suspicious
for newly discovered metastases leading to biopsy. Group 2 consists of
patients for whom the first available imaging showed lesions suspicious for
liver metastases.
Histologic means that the primary tumor was known prior to liver biopsy by
either biopsy or resection of the primary tumor and/or a nonhepatic metas-
tasis. Imaging means that the primary tumor was diagnosed based on clas-
sic imaging findings.
Figure 2. (Top) Axial computed tomography (CT) image of
an 83-year-old man with history of transitional cell carcinoma
is shown. (Bottom) Axial CT image from a CT urogram per-
formed 12 months later shows an ill-defined lesion (arrow) in
the left hepatic lobe. Biopsy of this lesion showed adenocar-
cinoma secondary to a colorectal primary tumor.
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assumed that if any liver biopsy matched the known pri-
mary malignancy, the patient would be treated as such. A
similar assumption was made for patients whose liver bi-
opsy uncovered a new malignancy. For patients whose
liver biopsy showed a benign diagnosis, we assumed they
would be treated as having no metastases. For patients
with nondiagnostic biopsies, we determined how they
were treated from chart review. Of the 575 patients where
management was known or presumed, 515 (89.6%) were
treated the same as they would have been if the imaging
findings had been considered diagnostic of hepatic metas-
tases from the known primary malignancy. Thirty (5.2%)
had a second malignancy uncovered and were managed
accordingly, and 30 (5.2%) were managed as if they did
not have hepatic metastases. However, because the medi-
cal records did not include a treatment plan proposed
before the liver biopsy results became available, we do not
know how many of these last 60 patients actually had spe-
cific treatment alterations from the treatment they would
have received if they had been assumed to have hepatic
metastases from their known primary malignancy.
Complications were documented for only 4 (0.7%)
of 580 liver biopsies in our series (3 patients developed
pneumothorax that needed treatment by chest tube, and 1
had vasovagal hypotension). No fatalities occurred.
DISCUSSION
When a patient presents with imaging findings that raise
suspicion of hepatic metastases, a percutaneous image-
guided biopsy of the liver is often obtained to confirm
that diagnosis. For patients without a known malignancy,
this procedure, when successful, returns a histologic diag-
nosis that not only confirms the presence of metastases,
but also suggests what the primary neoplasm may be.
However, the efficacy of a liver biopsy is less clear in
patients who have a primary malignancy known from his-
tologic biopsy of that tumor or 1 of its nonhepatic metas-
tases, or who have imaging findings that strongly suggest a
specific primary neoplasm. For these patients, it is reason-
able to ask if the biopsy procedure simply confirms the
expected result. The aim of our investigation was to assess
the diagnostic yield of percutaneous image-guided liver
biopsy in the diagnosis of suspicious focal hepatic lesions
in patients with a known primary malignancy and to
determine how often the biopsy result was unexpectedly
negative, benign, or secondary to a second unknown
malignancy.
Complications such as hemorrhage and vasovagal
reaction have been reported to occur in 0.6% of liver
biopsies.1 Although rare, it has been reported that hemor-
rhage can be fatal in 1=3 of liver biopsies that are compli-
cated by hemorrhage.2 In another series of 68,276 liver
Figure 3. Marginally enhancing lesion (arrow) is shown in the
posterior right lobe in a 67-year-old man with a history of re-
nal cell carcinoma. Biopsy of the lesion showed dense scar-
ring and old hemorrhage with chronic inflammation related
to an old abscess. The patient had no prior imaging at our
facility.














Histologic 14 8 4a 26
Imaging 1 0 0 1
Total 15 (56) 8 (30) 4 (15) 27
Five of the 32 patients who underwent nondiagnostic biopsies were lost to follow-up.
Parentheses indicate total percentages, which are calculated based on the remaining 27 known outcomes.
Histologic means that the primary tumor was known prior to liver biopsy by either biopsy or resection of the primary tu-
mor and/or a nonhepatic metastasis. Imaging means that the primary tumor was diagnosed based on classic imaging
findings.
a See text for outcomes of these 4 cases.
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biopsies, death, serious hemorrhagic complications, pneu-
mothorax, and biliary peritonitis were reported to compli-
cate 0.1% to 0.3% of liver biopsies.3 In our study,
complications were documented for 4 (0.7%) of 580 cases
(3 developed pneumothorax that was treated by chest
tube insertion, and 1 had vasovagal hypotension); none of
these complications was fatal.
The diagnostic yield of percutaneous image-guided
liver biopsy was investigated by several authors. Schmidt
et al4 reported relatively low diagnostic yield of 61%,
67%, and 61% for hepatic biopsies guided by MRI, CT,
and ultrasound, respectively. Other series documented a
significantly higher rate of accuracy of up to 98.6%.5
Small lesion size and image artifacts accounted for signifi-
cantly important reasons leading to diagnostic inaccuracy
of biopsy.6-8 In our study, hepatic biopsy yielded non-
diagnostic results in 32 cases (5.5% of the total number of
cases). Of these 32 cases, 5 were lost to follow-up, and 10
were treated as if they did not have metastatic disease. Me-
tastases from the known primary neoplasm were assumed
in 15 (56% of the 27 cases for which follow-up is avail-
able). Two had malignancy proven by other means (1
with a match to the primary histology and 1 with the find-
ing of a second malignancy).
Our study found a high positive yield for the initial
image-guided liver biopsy, which produced a diagnosis in
548 (94.5%) of 580 cases. Hepatic biopsy yielded malig-
nant results in 528 (91%) of the 580 patients who had a
primary tumor known from prior histology or characteris-
tic imaging. Of these, 499 (94.5% of malignancy-positive
biopsies and 86.0% of all cases) biopsies matched the pa-
thology of the primary malignancy. In 29 (5.5% of malig-
nancy-positive biopsies and 5% of all cases), liver biopsies
revealed a malignancy that was different from the primary
pathology. In 20 (3.4%) of 580 cases, a benign diagnosis
was obtained at initial image-guided biopsy.
The clinical management of the 32 initial liver biop-
sies that were nondiagnostic raises some interesting issues.
Apart from the 5 patients who were lost to follow-up after
the initial biopsy, we found that 23 patients were managed
as either positive (n¼15) or negative (n¼8) for metastases
without additional histologic sampling, and 4 patients
were referred for additional biopsies. We were unable in
this retrospective study to determine why these different
pathways were chosen, but it could relate to specific clini-
cal factors (for example, the clinical assessment of the pre-
test probability of hepatic metastases, or limited difference
in the treatments available) or to clinician or patient ability
to deal with diagnostic uncertainty. In the 4 patients who
underwent a second image-guided liver biopsy (and even a
third such biopsy in 1 of these 4 patients), none of these
biopsies was positive for malignancy. Although the sample
size is small, this suggests that it may be more productive
to seek an alternate method of diagnosis, if 1 is available
and indicated, than repeat liver biopsy. Conversely, of the
3 patients who had further interventions to obtain tissue,
2=3 did have malignant disease, and 1=3 had a benign hepatic
lesion. Despite the small numbers, this spread might call
into question the decision in 23 patients to manage them
without further histologic investigation, although it is
interesting that the distribution of management (65%
managed as having metastases and 35%managed as having
Figure 4. (Top) Axial computed tomography (CT) section of
a 50-year-old man with a history of biopsy-proven retroperi-
toneal sarcoma is shown. (Bottom) Axial CT image 10 months
later shows new low-attenuation lesions in the caudate lobe
(arrow) and posterior segment of the right hepatic lobe. The
right lobe lesion was biopsied twice, with nondiagnostic
results both times. The patient was eventually found to have
metastatic disease from the sarcoma primary malignancy af-
ter a third biopsy performed using endoscopic ultrasound.
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no metastases) almost exactly mirrors the results in the 3
patients in whom diagnostic tissue was obtained.
Our retrospective study has some limitations.
Patients whose first available scans showed suspicious liver
lesions (Group 2) may have had prior negative liver imag-
ing at another institution and thus might have been placed
in Group 1 if we had had access to all imaging performed
on patients, including outside studies. Indeed, it is logical
to assume that if scanned at the appropriate time, all
patients would at some point have had a negative study
for liver metastases before the study that led to the liver bi-
opsy. Approximately 1 in 5 patients (112 of 580, or
19.3%) did not have histologic proof of their primary
malignancy, instead having imaging findings characteris-
tic of a specific primary diagnosis. However, the rate of
unexpected findings (second malignancy, benign lesion,
or nondiagnostic biopsy) was lower for patients with
imaging diagnosis of primary neoplasm than for patients
with histologically proven primary neoplasm (4.5% vs
16.2%, respectively). Although we carefully checked avail-
able medical records to determine what diagnoses of pri-
mary neoplasm were known or suspected by imaging at
the time of the liver biopsy, it is conceivable that some of
the 29 patients whose liver biopsy revealed a metastasis
from a malignancy different from that expected had had
another malignancy proven at another institution of
which our clinicians were unaware. However, we believe
that our study would still reflect normal clinical practice
and decision making.
No attempt was made to retrospectively re-evaluate
the appropriateness of the clinical decision making,
because the goal of the study was to evaluate liver biopsy
as used in clinical practice. For the same reason, we did
not retrospectively review the imaging findings of the
lesions to evaluate the accuracy of the original interpreta-
tions or whether additional studies might have obviated
the need for biopsy. For example, it is possible that some
of the benign lesions could have been diagnosed noninva-
sively by MRI. In a series of 124 CT-indeterminate focal
hepatic lesions, MRI was able to well characterize approxi-
mately 60% of these lesions.9
From the above results, we conclude that if all liver
lesions had been assumed to be metastases, as expected
secondary to the known primary tumor, then the true
alternate diagnosis would have been missed in 51 (8.9%)
of 575 cases with follow-up in which a benign liver lesion
or alternate malignancy was instead found by initial
image-guided biopsy or other means. In an additional 9
(1.6%) cases, patients were assumed to be free of hepatic
metastases without a proven histologic diagnosis of the
liver lesions. Thus in 60 cases (10.4% of 575 cases with
follow-up and 10.3% of all 580 cases), there is the possi-
bility of different patient management than if all patients
were assumed to have hepatic metastases from their
known primary neoplasms. Because of the extreme diffi-
culty in doing so in a retrospective study, we did not
attempt to determine whether actual clinical management
changed in these 60 cases, so this number is an upper
bound on management change. (For example, some
patients might have been referred to hospice care in any
case.) Similarly, without knowing the changes in clinical
management and their presumed benefit to the patient,
Table 4. Known or Presumed Management of Patients Based on Hepatic Biopsy Result












Consistent with known primary malignancy 499
Consistent with newly uncovered malignancy 29
Nondiagnostic
After first biopsy, treated as metastases 15
After first biopsy, treated as no metastases 8
After second biopsy, treated as no metastases 1
After lesion resection, treated as no metastases 1
Third biopsy consistent with known primary malignancy 1
Third biopsy consistent with newly uncovered malignancy 1
Benign 20
Total 515 30 30
Five of 580 patients had a nondiagnostic liver biopsy and then were lost to follow-up.
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we could not estimate the cost-effectiveness of liver biopsy
in this population in which about 90% of the biopsies
give the expected result. Fortunately, complications were
few and relatively mild.
In this era of tighter healthcare dollars, it might be
tempting to save the cost of liver biopsy by assuming that
the result is a foregone conclusion. One important impli-
cation of our work is to refute any unconsidered proposi-
tion that patients with known or suspected primary
neoplasms with apparent hepatic metastases by CT imag-
ing should be routinely treated as if they have the expected
metastases without further evaluation to save healthcare
expenditures. To properly deliberate this concept requires
cost-effectiveness analyses that are beyond the scope of
this work, but may be considered as opportunities for
future research, perhaps using decision analytic
techniques.10
At the outset of the study, we wondered if liver bi-
opsy in this patient population was really necessary, or
simply always confirmed the clinical concern for metasta-
sis from a known primary tumor. Although it was the case
that the vast majority of biopsies in our series did not
change patient management, we were surprised to find
such a high percentage of cases in which the biopsy result
of a presumed hepatic metastasis was different from the
patient’s known primary tumor, including 5.2% (30 of
580) that had a second unknownmalignancy.
Given the current ability of imaging (particularly
MRI) to make specific benign diagnoses of liver lesions,
we were surprised that 3.6% (21 of 580) of biopsied
lesions were proven to be of benign histology at initial bi-
opsy (n ¼ 20) or subsequent resection (n ¼ 1). Because
this is a biopsy-only series, we do not know how many
patients with primary neoplasms did not have hepatic
biopsies because imaging techniques showed that their
liver lesions were benign. Nevertheless, our results argue
for careful assessment of hepatic lesions found on CT
scans in patients with neoplasms, rather than simply
reflexively jumping to biopsy. We recognize that in many
cases, metastasis is nearly certain from the CT imaging
appearance, and in those cases biopsy may be appropriate,
because we have shown that metastases may be from a dif-
ferent primary tumor than expected. Conversely, we pro-
pose that, to avoid biopsy in some patients, it would be
appropriate to perform MRI in an attempt to noninva-
sively determine a diagnosis whenever there is any sugges-
tion based on CT imaging criteria that a suspicious
hepatic lesion may be benign, or clinical suspicion that
liver metastasis might be unlikely.
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